|
Dr. Apelian's therapeutic area experience includes inflammatory bowel disease, hepatitis C and hepatitis B. Dr. Apelian came to GlobeImmune from Bristol-Myers Squibb where he served as a Clinical Director in the Infectious Diseases Group acting as medical lead for clinical development for the Baraclude (entecavir) NDA filing and approval in chronic hepatitis B. Prior to that, he served as Clinical Director in the Department of Hepatology / Gastroenterology at Schering Plough where he was medical lead on the pediatric sNDA for Rebetron for chronic HCV. Dr. Apelian received his M.D. from the University of Medicine and Dentistry of New Jersey, a Ph.D. in Biochemistry from Rutgers University, and an M.B.A. from Quinnipiac University. Dr. Apelian is board certified in Pediatrics. | 